C7B-C7B
Medium Complexity

Secondary neuroendocrine tumors

Primary Specialty: Oncology
Last Updated: 2025-09-09

ICD-10 Codes (0)

0 billable
0 category headers

No codes found matching your search

Updates & Changes

FY 2026 Updates

Current Year

New Codes (2)

C02.9
Malignant neoplasm of tongue, unspecified, HPV-positive
C10.8
Malignant neoplasm of overlapping sites of oropharynx, HPV-positive

Revised Codes (2)

C01
Malignant neoplasm of base of tongue - updated to include HPV status when known
C09.9
Malignant neoplasm of tonsil, unspecified - enhanced molecular classification

Deleted Codes

No codes deleted in this range for FY 2026

Historical Changes

  • FY 2025: Routine maintenance updates with minor terminology clarifications
  • FY 2024: Enhanced specificity requirements for certain code ranges
  • FY 2023: Updated documentation guidelines for improved clarity

Upcoming Changes

  • Proposed updates pending review by Coordination and Maintenance Committee
  • Under consideration: Enhanced digital health integration codes

Implementation Guidance

  • Review all FY 2026 updates for C7B-C7B codes before implementation
  • Always verify the most current codes in the ICD-10-CM manual
  • Ensure clinical documentation supports the selected diagnosis codes
  • +3 more guidance items...

Range Overview

high priority

The ICD-10 code range C7B-C7B is specifically designated for secondary neuroendocrine tumors. These codes are used to classify and document neuroendocrine tumors that have metastasized from their original site to other parts of the body. The codes within this range are highly specific, allowing for detailed documentation of the tumor's location and type.

Key Usage Points:

  • Always specify the location of the secondary neuroendocrine tumor.
  • Use additional codes to document any associated complications.
  • If the primary site of the tumor is known, document it using the appropriate code.
  • If the tumor is malignant, use the appropriate code to document this.
  • Always verify the code against the latest ICD-10 manual.

Coding Guidelines

When to Use:

  • When a patient has a neuroendocrine tumor that has metastasized.
  • When the primary site of the tumor is known.
  • When the tumor is malignant.
  • When the patient has complications associated with the tumor.

When NOT to Use:

  • When the tumor is benign.
  • When the tumor is primary, not secondary.
  • When the patient has a non-neuroendocrine tumor.
  • When the tumor has not metastasized.

Code Exclusions

Always verify exclusions against the latest ICD-10 manual.

Documentation Requirements

Documentation for secondary neuroendocrine tumors should be comprehensive and detailed. It should include information about the tumor's location, type, malignancy status, and any associated complications.

Clinical Information:

  • Location of the secondary tumor
  • Type of neuroendocrine tumor
  • Status of malignancy
  • Associated complications

Supporting Evidence:

  • Pathology reports
  • Imaging studies
  • Operative reports
  • Clinical notes
Good Documentation Example:

Patient has a malignant secondary neuroendocrine tumor in the liver, originating from the pancreas. Complications include liver dysfunction.

Poor Documentation Example:

Patient has a neuroendocrine tumor.

Common Documentation Errors:

  • Not specifying the location of the tumor
  • Not documenting the malignancy status
  • Not using additional codes for associated complications
  • Not documenting the primary site of the tumor if known

Range Statistics

Total Codes
0
Billable
Complexity:
Medium
Primary Use:Clinical Documentation
Chapter:2

Coding Complexity

Medium
Complexity Rating

The coding complexity for the C7B-C7B range is medium due to the need for detailed documentation and the use of additional codes for complications. Coders must also determine the location and type of the tumor, as well as its malignancy status.

Key Factors:
  • Determining the location of the secondary tumor
  • Determining the type of neuroendocrine tumor
  • Documenting the malignancy status
  • Using additional codes for associated complications

Specialty Focus

The C7B-C7B code range is most commonly used by oncologists and endocrinologists. It may also be used by gastroenterologists and pulmonologists, depending on the location of the tumor.

Primary Specialties:
Oncology
60%
Endocrinology
30%
Clinical Scenarios:
  • A patient with a history of pancreatic neuroendocrine tumor presents with liver dysfunction. Imaging reveals a secondary tumor in the liver.
  • A patient with carcinoid syndrome is found to have a secondary neuroendocrine tumor in the lung.
  • A patient with a known neuroendocrine tumor presents with new-onset bone pain. Imaging reveals a secondary tumor in the spine.

Resources & References

Resources for the C7B-C7B code range include the latest ICD-10 manual, clinical guidelines for neuroendocrine tumors, and educational materials on medical coding.

Official Guidelines:

  • ICD-10-CM Official Guidelines for Coding and Reporting
  • National Comprehensive Cancer Network (NCCN) Guidelines for Neuroendocrine Tumors
  • World Health Organization (WHO) Classification of Tumours

Clinical References:

  • American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines
  • European Society for Medical Oncology (ESMO) Clinical Practice Guidelines

Educational Materials:

  • American Health Information Management Association (AHIMA) ICD-10 Training Materials
  • American Academy of Professional Coders (AAPC) ICD-10 Coding Resources

Frequently Asked Questions

Can I use a C7B code for a primary neuroendocrine tumor?

No, the C7B-C7B range is specifically for secondary neuroendocrine tumors. Primary tumors should be coded using the C7A.0-C7A.8 range.